Waiakea Water: Promoting Healthy Drinking

It is no secret that Hawaii is a land of immense beauty and breathtaking coastal beaches. It is for this reason that the people of Hawaii take pride in safeguarding their rich history and culture. The crystal clear water that flows from the snow-capped mountains down the slopes of Mauna Loa Volcano attracted the inception and presence of Waiakea Inc.
Waiakea Inc. is a water bottling company that deals with the production and supply of Hawaiian volcanic purified water. Waiakea Inc. gets its highly-enriched water from the slopes of the highly-active Mauna Loa Volcano which also happens to be one of the world’s leading source of fresh water.
Waiakea Inc. uses high-grade Recycled Polyethylene Terephthalate (RPET) for all of its bottles, giving you the peace of mind that the water you are consuming is clean. The notion behind this is based on the fact the bottles used are BPA free which simply means that the Waiakea bottled water that you consume is free of harmful chemicals that may pose a threat to your well-being. Apart from this, RPET bottles usually save close to 85% of the energy used in manufacturing them as compared to other regular bottles. Another advantage of RPET bottles is the fact that they use close to 90% of less water as compared to regular bottles while at the same time, their overall carbon emission is less than 10%.
About Waiakea Inc. 
Waiakea Inc. was founded in the year 2012 by Ryon Emmons. For a period of five years, Waiakea has been a force to reckon with, not only in Hawaii but also in the neighboring countries. As a matter of fact, Waiakea Inc. became the first ever company to be awarded the CarbonNeutral Certification. This award cemented Waiakea Inc. presence as a company that embraces an eco-friendly environment by preserving the ecosystem of Hawaii. Waiakea Inc. brings together the rich history of Hawaii, the Hawaiian culture, and advanced technology to produce bottled water that incorporates mother nature in mind.
Waiakea is a team player in solving the water crisis. For every liter of water bought, Waiakea donates 450 liters of clean water to the less-privileged communities in Africa through the Pump Aid organization.

Expansion and Projects of Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company in the United States of America. It started operating in the February of 2002 with headquarters set up in Cranbury, new jersey. The company has as chief executive officer Mr. John F. Crowley who has been with Amicus Therapeutics for many years.

The company of Amicus Therapeutics is focused on creating therapies for disorders with the collective name of lysosomal storage disorders. Amicus Therapeutics is also sharply focused on conducting research. In fact, the company has a couple of sites for research – one in New Jersey and another in San Diego.

The journey of the business of Amicus Therapeutics has been eventful. Up until 2009, Amicus Therapeutics was doing quite well. The company expanded and started up its second research location in 2008 in San Diego.

However, in 2009, Amicus Therapeutics was faced with a major setback. It had not manufacture power of its own, and it had been relying on a contract with Shire. Over the next couple of years, Amicus Therapeutics received grants from foundations such as The Michael J. Fox Foundation, the Alzheimer’s Drug Discovery Foundation, and a few others.

By 2013, Amicus Therapeutics was restored to its former self, and it even took on a few projects to expand the business. Towards the end of 2013, in November, Amicus Therapeutics made its first acquisition. Callidus Biopharma was obtained as well as some proprietary materials as well as intellectual property for a therapy treatment, again, based on enzyme replacement. After a couple of years, Amicus Therapeutics had another acquisition, and it obtained Scioderm for the cost of almost one billion dollars.

Amicus Therapeutics has as a leader the CEO Mr. John F. Crowley who has been a part of the company since the years of 2005. Five years later, in 2010, CEO Mr. John F. Crowley also assumed the responsibilities of chairman of the board. The previous chairman took up the position of Lead Independent Director instead.

Over the past couple of years, Amicus Therapeutics has been growing steadily in the industry of biopharmaceuticals. The company currently has well over a hundred employees and is undergoing an expansion project.